JPWO2021257420A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021257420A5
JPWO2021257420A5 JP2022577341A JP2022577341A JPWO2021257420A5 JP WO2021257420 A5 JPWO2021257420 A5 JP WO2021257420A5 JP 2022577341 A JP2022577341 A JP 2022577341A JP 2022577341 A JP2022577341 A JP 2022577341A JP WO2021257420 A5 JPWO2021257420 A5 JP WO2021257420A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
aryl
methyl
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022577341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530320A (ja
JP2023530320A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/037160 external-priority patent/WO2021257420A1/en
Publication of JP2023530320A publication Critical patent/JP2023530320A/ja
Publication of JP2023530320A5 publication Critical patent/JP2023530320A5/ja
Publication of JPWO2021257420A5 publication Critical patent/JPWO2021257420A5/ja
Pending legal-status Critical Current

Links

JP2022577341A 2020-06-17 2021-06-14 Nav1.8阻害剤としての5-オキソピロリジン-3-カルボキサミド Pending JP2023530320A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063040465P 2020-06-17 2020-06-17
US63/040,465 2020-06-17
PCT/US2021/037160 WO2021257420A1 (en) 2020-06-17 2021-06-14 5-oxopyrrolidine-3-carboxamides as nav1.8 inhibitors

Publications (3)

Publication Number Publication Date
JP2023530320A JP2023530320A (ja) 2023-07-14
JP2023530320A5 JP2023530320A5 (https=) 2024-06-20
JPWO2021257420A5 true JPWO2021257420A5 (https=) 2024-06-20

Family

ID=79268285

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022577341A Pending JP2023530320A (ja) 2020-06-17 2021-06-14 Nav1.8阻害剤としての5-オキソピロリジン-3-カルボキサミド

Country Status (10)

Country Link
US (1) US20230227405A1 (https=)
EP (1) EP4167993A4 (https=)
JP (1) JP2023530320A (https=)
KR (1) KR20230026405A (https=)
CN (1) CN115697327A (https=)
AU (1) AU2021292062A1 (https=)
BR (1) BR112022024476A2 (https=)
CA (1) CA3180372A1 (https=)
MX (1) MX2022015580A (https=)
WO (1) WO2021257420A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023530319A (ja) 2020-06-17 2023-07-14 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害剤としての2-オキソ-オキサゾリジン-5-カルボキサミド
MX2023013147A (es) * 2021-05-07 2023-11-28 Merck Sharp & Dohme Llc Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
EP4334293A1 (en) * 2021-05-07 2024-03-13 Merck Sharp & Dohme LLC Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
WO2022256676A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
MA64856B1 (fr) 2021-06-04 2026-02-27 Vertex Pharmaceuticals Incorporated Formes de dosage solides et regimens de dosage comprenant le [[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl) tétrahydrofuranne-2-carbonyl]amino]pyridine-2-carboxamide
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
CA3221788A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
JP2024520646A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのn-(ヒドロキシアルキル(ヘテロ)アリール)テトラヒドロフランカルボキサミド類似体
JP2024520643A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としてのヒドロキシ及び(ハロ)アルコキシ置換テトラヒドロフラン
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
UY40234A (es) 2022-04-22 2023-11-15 Vertex Pharma Compuestos heteroarilo para el tratamiento del dolor
GEAP202516634A (en) 2022-04-22 2025-02-25 Vertex Pharma Heteroaryl compounds for the treatment of pain
JP2025513452A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
IL316433A (en) 2022-04-25 2024-12-01 Siteone Therapeutics Inc Bicyclic heterocyclic amide inhibitors of NA v1.8 for the treatment of pain
AU2023391870A1 (en) 2022-12-06 2025-06-05 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025122953A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
US8202861B2 (en) * 2003-08-08 2012-06-19 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
GB0514017D0 (en) * 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
US8710043B2 (en) * 2011-06-24 2014-04-29 Amgen Inc. TRPM8 antagonists and their use in treatments
WO2014146111A2 (en) * 2013-03-15 2014-09-18 The Regents Of The University Of California Analgesic compounds and methods of use
CA2979534A1 (en) * 2015-03-13 2016-09-22 Abbvie Inc. (indazol-4-yl)hexahydropyrrolopyrrolones and method of use

Similar Documents

Publication Publication Date Title
JPWO2021257420A5 (https=)
JPWO2021257418A5 (https=)
JP2024038267A5 (https=)
JP2024119812A5 (https=)
JP2017525757A5 (https=)
JP5277168B2 (ja) 血小板過剰を治療するbclインヒビター
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
JP2023123854A5 (https=)
JP2001526223A5 (https=)
JP2021523221A5 (https=)
JP2007502806A5 (https=)
RU2315041C2 (ru) Производные 2,6-хинолинила и 2,6-нафтила, фармацевтические композиции на их основе, их применение в качестве ингибиторов vla-4 и промежуточные соединения
RU2009136263A (ru) Производные бензимидазола и способы их применения
SI2961736T1 (en) Histone demethylase inhibitors
RU2006112428A (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
CA2418868A1 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
RU2006109600A (ru) N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
JP2004506632A5 (https=)
JP2017509694A5 (https=)
JP2004502670A5 (https=)
RU2019136279A (ru) C5 -Анилинохиназолиновые соединения и их использование в лечении рака
JP2007502295A5 (https=)
RU2008138163A (ru) 4-фенилтиазол-5-карбоновые кислоты и амиды 4-фенилтиазол-5-карбоновой кислоты как ингибиторы polo-подобной киназы plk1
JP2013530957A5 (https=)